Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TLR2 | O60603 | 1/20 | 0.32 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13008106 | 1.00 | KDM4E (0.38) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL19285817 | 1.00 | KDM4E (0.38) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL12092173 | 1.00 | KDM4E (0.38) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL26418491 | 1.00 | KDM4E (0.38) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL30761906 | 0.94 | TSHR (0.33) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL25297487 | 0.90 | KDM4E (0.44) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL22367555 | 0.90 | KDM4E (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL17911521 | 0.89 | KDM4E (0.43) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL19434631 | 0.86 | KDM4E (0.38) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL18095448 | 0.86 | KDM4E (0.38) | KDM4EUSP2ALDH1A1LMNAMMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12220419-B2 | BCL-2 inhibitors | NEWAVE PHARMACEUTICAL INC. (US) | 2025-02-11 | — | — | US | disclosed |
| US-20240382599-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-11-21 | — | — | US | disclosed |
| US-20240197810-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC. | 2024-06-20 | — | — | US | disclosed |
| US-11819531-B2 | Multifunctional zwitterionic polymer conjugates | KODIAK SCIENCES INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11819531-B2 | Multifunctional zwitterionic polymer conjugates | KODIAK SCIENCES INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11819531-B2 | Multifunctional zwitterionic polymer conjugates | KODIAK SCIENCES INC. (US) | 2023-11-21 | — | — | US | disclosed |
| EP-3659591-B1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-3659591-B1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230277616-A9 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230277616-A9 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC. | 2023-09-07 | — | — | US | disclosed |
| EP-2512462-B1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC (US) | 2017-08-23 | — | — | EP | disclosed |
| US-20160287715-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160287715-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160287715-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC (US) | 2016-10-06 | — | — | US | disclosed |
| US-20130045522-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | OLIGASIS (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130045522-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | OLIGASIS (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130045522-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | OLIGASIS (US) | 2013-02-21 | — | — | US | disclosed |
| EP-2512462-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | Oligasis (US) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011075736-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | OLIGASIS (US) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011075736-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | OLIGASIS (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230277616-A9 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | PHOSPHO1, MSN, ZW10 | KDM4E 4653/4885USP2 1536/4885ALDH1A1 4195/4885 |
| US-20160287715-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | PHOSPHO1, MSN, ZW10 | KDM4E 4653/4885USP2 1536/4885ALDH1A1 4195/4885 |
| US-20240382599-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | TBK1, EGFR, CBL | KDM4E 1254/4885USP2 45/4885ALDH1A1 4031/4885 |
| US-12220419-B2 | BCL-2 inhibitors | BCL2L10, BCL2, BCL2L11 | KDM4E 532/4885USP2 1563/4885ALDH1A1 3743/4885 |
| US-20240197810-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | PHOSPHO1, MSN, ZW10 | KDM4E 4653/4885USP2 1536/4885ALDH1A1 4195/4885 |
| US-11819531-B2 | Multifunctional zwitterionic polymer conjugates | PHOSPHO1, MSN, ZW10 | KDM4E 4653/4885USP2 1536/4885ALDH1A1 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.